Merck & Co., Inc. Research and Development Asset Acquired Other than Through Business Combination, Written-off
Merck & Co., Inc. (MRK) reported Research and Development Asset Acquired Other than Through Business Combination, Written-off of $13.81 billion for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff · last filed 2026-08-07
- Merck & Co., Inc. research and development asset acquired other than through business combination, written-off for the quarter ending 2026-06-30 was $5.27B.
- Merck & Co., Inc. research and development asset acquired other than through business combination, written-off for the quarter ending 2026-03-31 was $8.54B.
- Merck & Co., Inc. research and development asset acquired other than through business combination, written-off for the quarter ending 2025-12-31 was $0.00, a 100.00% decline year-over-year.
- Merck & Co., Inc. research and development asset acquired other than through business combination, written-off for the quarter ending 2025-09-30 was $0.00, a 100.00% decline year-over-year.
- Merck & Co., Inc. research and development asset acquired other than through business combination, written-off for fiscal 2025 was $0.00, a 100.00% decline from fiscal 2024.
- Merck & Co., Inc. research and development asset acquired other than through business combination, written-off for fiscal 2024 was $3.46B, a 69.71% decline from fiscal 2023.
- Merck & Co., Inc. research and development asset acquired other than through business combination, written-off for fiscal 2023 was $11.41B.
- Merck & Co., Inc. research and development asset acquired other than through business combination, written-off for fiscal 2022 was $0.00, a 100.00% decline from fiscal 2021.
| Period end | Research and Development Asset Acquired Other than Through Business Combination, Written-off 3 month | Research and Development Asset Acquired Other than Through Business Combination, Written-off 3 month as first filed | Research and Development Asset Acquired Other than Through Business Combination, Written-off 6 month | Research and Development Asset Acquired Other than Through Business Combination, Written-off 6 month as first filed | Research and Development Asset Acquired Other than Through Business Combination, Written-off 9 month | Research and Development Asset Acquired Other than Through Business Combination, Written-off 9 month as first filed | Research and Development Asset Acquired Other than Through Business Combination, Written-off 12 month | Research and Development Asset Acquired Other than Through Business Combination, Written-off 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $5.27B derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-07 | $13.81B 10-Q · filed 2026-08-07 | $13.81B derived: sum of 3 quarters · filed 2026-08-07 | $13.81B derived: sum of 4 quarters · filed 2026-08-07 | ||||
| 2026-03-31 | $8.54B 10-Q · filed 2026-05-04 | $8.54B derived: sum of 2 quarters · filed 2026-05-04 | $8.54B derived: sum of 3 quarters · filed 2026-05-04 | $8.54B derived: sum of 4 quarters · filed 2026-08-07 | ||||
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $0.00 derived: sum of 2 quarters · filed 2026-02-24 | $0.00 derived: sum of 3 quarters · filed 2026-08-07 | $0.00 10-K · filed 2026-02-24 | ||||
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $0.00 derived: sum of 2 quarters · filed 2026-08-07 | $0.00 10-Q · filed 2025-11-05 | $700.00M derived: sum of 4 quarters · filed 2026-08-07 | ||||
| 2025-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-07 | $0.00 10-Q · filed 2026-08-07 | $700.00M derived: sum of 3 quarters · filed 2026-08-07 | $2.80B derived: sum of 4 quarters · filed 2026-08-07 | ||||
| 2025-03-31 | $0.00 10-Q · filed 2026-05-04 | $700.00M derived: sum of 2 quarters · filed 2026-05-04 | $2.80B derived: sum of 3 quarters · filed 2026-05-04 | $2.80B derived: sum of 4 quarters · filed 2026-05-04 | ||||
| 2024-12-31 | $700.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $2.80B derived: sum of 2 quarters · filed 2026-02-24 | $2.80B derived: sum of 3 quarters · filed 2026-02-24 | $3.46B 10-K · filed 2026-02-24 | ||||
| 2024-09-30 | $2.10B derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $2.10B derived: sum of 2 quarters · filed 2025-11-05 | $2.76B 10-Q · filed 2025-11-05 | $0.00 10-Q · filed 2024-11-06 | $12.97B derived: sum of 4 quarters · filed 2026-02-24 | |||
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-05 | $656.00M 10-Q · filed 2025-08-05 | $0.00 10-Q · filed 2024-08-05 | $10.87B derived: sum of 3 quarters · filed 2026-02-24 | $10.87B derived: sum of 4 quarters · filed 2026-02-24 | |||
| 2024-03-31 | $656.00M 10-Q · filed 2025-05-02 | $0.00 10-Q · filed 2024-05-03 | $10.87B derived: sum of 2 quarters · filed 2026-02-24 | $10.87B derived: sum of 3 quarters · filed 2026-02-24 | $10.87B derived: sum of 4 quarters · filed 2026-02-24 | |||
| 2023-12-31 | $10.22B derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $10.22B derived: sum of 2 quarters · filed 2026-02-24 | $10.22B derived: sum of 3 quarters · filed 2026-02-24 | $11.41B 10-K · filed 2026-02-24 | $0.00 10-K · filed 2024-02-26 | |||
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | $0.00 derived: sum of 2 quarters · filed 2024-11-06 | $1.19B 10-Q · filed 2024-11-06 | $1.19B derived: sum of 4 quarters · filed 2025-02-25 | ||||
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-05 | $1.19B 10-Q · filed 2024-08-05 | $1.19B derived: sum of 3 quarters · filed 2025-02-25 | $1.19B derived: sum of 4 quarters · filed 2025-02-25 | ||||
| 2023-03-31 | $1.19B 10-Q · filed 2024-05-03 | $1.19B derived: sum of 2 quarters · filed 2025-02-25 | $1.19B derived: sum of 3 quarters · filed 2025-02-25 | $1.19B derived: sum of 4 quarters · filed 2025-02-25 | ||||
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-25 | $0.00 derived: sum of 2 quarters · filed 2025-02-25 | $0.00 derived: sum of 3 quarters · filed 2025-02-25 | $0.00 10-K · filed 2025-02-25 | ||||
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-03 | $0.00 derived: sum of 2 quarters · filed 2023-11-03 | $0.00 10-Q · filed 2023-11-03 | $0.00 derived: sum of 4 quarters · filed 2024-02-26 | ||||
| 2022-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-07 | $0.00 10-Q · filed 2023-08-07 | $0.00 derived: sum of 3 quarters · filed 2024-02-26 | $0.00 derived: sum of 4 quarters · filed 2024-02-26 | ||||
| 2022-03-31 | $0.00 10-Q · filed 2023-05-05 | $0.00 derived: sum of 2 quarters · filed 2024-02-26 | $0.00 derived: sum of 3 quarters · filed 2024-02-26 | |||||
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-26 | $0.00 derived: sum of 2 quarters · filed 2024-02-26 | $1.56B 10-K · filed 2024-02-26 | |||||
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | $1.56B 10-Q · filed 2022-11-03 | ||||||
| 2021-06-30 | $1.56B 10-Q · filed 2022-08-05 | |||||||
| 2020-12-31 | $0.00 10-K · filed 2023-02-24 | |||||||
| 2019-12-31 | $0.00 10-K · filed 2022-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AbbVie Inc. (ABBV) | United States | $468.180B | 70.37 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| JOHNSON & JOHNSON (JNJ) | United States | $652.528B | 29.10 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |